| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2013 ( Subtotal = -$437,398 ) |
| | 2013 | 2012 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA157090 | A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec | 000 | 2 | NIH | 9/26/2013 | -$437,398 |
|
| Issue Date FY: 2012 ( Subtotal = $979,500 ) |
| | 2012 | 2012 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA157090 | A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec | 000 | 2 | NIH | 5/28/2012 | $979,500 |
| | 2012 | 2011 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R44CA141936 | EARLY CLINICAL TESTING FOR MELANIN TARGETING RADIO-THERAPEUTIC AGENT IN MELANOMA | 000 | 3 | NIH | 1/4/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $1,976,205 ) |
| | 2011 | 2011 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R21CA141724 | TARGETING TUMOR HYPOXIA WITH RADIOHALOGENATED INHIBITORS OF CARBONIC ANHYDRASE IX | 001 | 2 | NIH | 5/18/2011 | $13,610 |
| | 2011 | 2011 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA141936 | EARLY CLINICAL TESTING FOR MELANIN TARGETING RADIO-THERAPEUTIC AGENT IN MELANOMA | 000 | 3 | NIH | 7/22/2011 | $737,540 |
| | 2011 | 2011 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R21CA141724 | TARGETING TUMOR HYPOXIA WITH RADIOHALOGENATED INHIBITORS OF CARBONIC ANHYDRASE IX | 000 | 2 | NIH | 2/14/2011 | $174,975 |
| | 2011 | 2011 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA142222 | DEVELOPMENT OF A MOLECULAR TARGETING AGENT FOR PSMA TO DIAGNOSE METASTATIC PROSTA | 000 | 4 | NIH | 5/25/2011 | $327,410 |
| | 2011 | 2011 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA138041 | SYSTEMIC RADIOTHERAPY FOR METASTATIC MELANOMAS: INNOVATION OF A NOVEL RADIOPHARMA | 000 | 4 | NIH | 8/11/2011 | $722,670 |
|
| Issue Date FY: 2010 ( Subtotal = $1,985,346 ) |
| | 2010 | 2010 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R43CA157090 | DEVELOPMENT OF A KIT BASED PET MOLECULAR IMAGING AGENT: EDOTREOTIDE GA 68 FOR SO | 000 | 1 | NIH | 9/17/2010 | $262,993 |
| | 2010 | 2010 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA142222 | DEVELOPMENT OF A MOLECULAR TARGETING AGENT FOR PSMA TO DIAGNOSE METASTATIC PROSTA | 002 | 3 | NIH | 5/14/2010 | $801,864 |
| | 2010 | 2010 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R21CA141724 | TARGETING TUMOR HYPOXIA WITH RADIOHALOGENATED INHIBITORS OF CARBONIC ANHYDRASE IX | 000 | 1 | NIH | 3/22/2010 | $111,095 |
| | 2010 | 2010 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R43CA150855 | A MOLECULAR TARGETING AGENT FOR SYSTEMIC RADIOTHERAPY OF METASTATIC PROSTATE CANC | 000 | 1 | NIH | 8/30/2010 | $243,101 |
| | 2010 | 2010 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R44CA138041 | SYSTEMIC RADIOTHERAPY FOR METASTATIC MELANOMAS: INNOVATION OF A NOVEL RADIOPHARMA | 000 | 3 | NIH | 9/17/2010 | $0 |
| | 2010 | 2010 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA141936 | EARLY CLINICAL TESTING FOR MELANIN TARGETING RADIO-THERAPEUTIC AGENT IN MELANOMA | 000 | 2 | NIH | 6/11/2010 | $559,294 |
| | 2010 | 2009 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA142222 | DEVELOPMENT OF A MOLECULAR TARGETING AGENT FOR PSMA TO DIAGNOSE METASTATIC PROSTA | 000 | 2 | NIH | 10/30/2009 | $6,999 |
| | 2010 | 2009 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA142222 | DEVELOPMENT OF A MOLECULAR TARGETING AGENT FOR PSMA TO DIAGNOSE METASTATIC PROSTA | 001 | 2 | NIH | 10/30/2009 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $2,301,537 ) |
| | 2009 | 2009 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA138041 | SYSTEMIC RADIOTHERAPY FOR METASTATIC MELANOMAS: INNOVATION OF A NOVEL RADIOPHARMA | 001 | 2 | NIH | 8/18/2009 | $911,810 |
| | 2009 | 2009 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA130394 | NANODOSING: A PATH TO HIGHER SENSITIVITY AND LOWER TOXICITY PHARMACEUTICALS | 000 | 3 | NIH | 8/12/2009 | $496,373 |
| | 2009 | 2009 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA141936 | EARLY CLINICAL TESTING FOR MELANIN TARGETING RADIO-THERAPEUTIC AGENT IN MELANOMA | 000 | 1 | NIH | 6/17/2009 | $223,985 |
| | 2009 | 2009 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R43CA141957 | TARGETING TUMOR MICROENVIRONMENT WITH RADIOLABELED INHIBITORS OF SEPRASE (FAPALPH | 000 | 1 | NIH | 6/16/2009 | $180,916 |
| | 2009 | 2009 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA142222 | DEVELOPMENT OF A MOLECULAR TARGETING AGENT FOR PSMA TO DIAGNOSE METASTATIC PROSTA | 000 | 2 | NIH | 9/28/2009 | $481,454 |
| | 2009 | 2009 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142-1515 | MIDDLESEX | USA | R44CA142222 | DEVELOPMENT OF A MOLECULAR TARGETING AGENT FOR PSMA TO DIAGNOSE METASTATIC PROSTA | 001 | 2 | NIH | 9/30/2009 | $6,999 |
| | 2009 | 2008 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R44CA138041 | SYSTEMIC RADIOTHERAPY FOR METASTATIC MELANOMAS: INNOVATION OF A NOVEL RADIOPHARMA | 000 | 1 | NIH | 10/31/2008 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $1,020,975 ) |
| | 2008 | 2008 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R44CA130394 | NANODOSING: A PATH TO HIGHER SENSITIVITY AND LOWER TOXICITY PHARMACEUTICALS | 000 | 2 | NIH | 9/9/2008 | $485,175 |
| | 2008 | 2008 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R44CA138041 | SYSTEMIC RADIOTHERAPY FOR METASTATIC MELANOMAS: INNOVATION OF A NOVEL RADIOPHARMA | 000 | 1 | NIH | 9/16/2008 | $331,449 |
| | 2008 | 2008 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R43CA134013 | RADIOLABELED INHIBITORS OF CARBONIC ANHYDRASE IX | 000 | 1 | NIH | 9/12/2008 | $204,351 |
|
| Issue Date FY: 2007 ( Subtotal = $482,120 ) |
| | 2007 | 2007 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R44CA115120 | DEVELOPING NANODOSING OF IOBENGUANE I 131 FOR RADIOTHERAPY | 000 | 3 | NIH | 9/5/2007 | $351,359 |
| | 2007 | 2007 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R44CA130394 | NANODOSING: A PATH TO HIGHER SENSITIVITY AND LOWER TOXICITY PHARMACEUTICALS | 000 | 1 | NIH | 7/11/2007 | $130,761 |
|
| Issue Date FY: 2006 ( Subtotal = $573,884 ) |
| | 2006 | 2006 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R44CA115120 | DEVELOPING NANODOSING OF IOBENGUANE I 131 FOR RADIOTHERAPY | 000 | 2 | NIH | 9/27/2006 | $573,884 |
|
| Issue Date FY: 2005 ( Subtotal = $577,688 ) |
| | 2005 | 2005 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R43CA115120 | HIGH SENSITIVITY AND LOW TOXICITY RADIOPHARMACEUTICALS | 000 | 1 | NIH | 3/17/2005 | $147,491 |
| | 2005 | 2005 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R43EB005858 | AN INSTANT KIT FOR 2-18FFLUORO-2-DEOXYGLUCOSE (FDG) | 000 | 1 | NIH | 9/14/2005 | $130,387 |
| | 2005 | 2005 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R41CA112797 | SIZE-DEPENDENT UPTAKE OF TC(I)-LABELED RGD ANALOGS | 000 | 1 | NIH | 1/12/2005 | $299,810 |
|
| Issue Date FY: 2004 ( Subtotal = $1,125,885 ) |
| | 2004 | 2004 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R43EB004253 | NOVEL GLUTAMATE CONJUGATES FOR RADIOTARGETING PSMA | 000 | 1 | NIH | 9/10/2004 | $327,234 |
| | 2004 | 2004 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R43EB004253 | NOVEL GLUTAMATE CONJUGATES FOR RADIOTARGETING PSMA | 000 | 1 | NIH | 9/10/2004 | $1 |
| | 2004 | 2004 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R43HL075918 | LABELED INHIBITORS FOR ANGIOTENSIN CONVERTING ENZYME | 000 | 1 | NIH | 4/19/2004 | $337,713 |
| | 2004 | 2004 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R43HL076972 | NOVEL ETHER CONTAINING LIGAND COMPLEXES: CARDIAC IMAGING | 000 | 1 | NIH | 4/26/2004 | $159,525 |
| | 2004 | 2004 | MOLECULAR INSIGHT PHARMACEUTICALS INC | 160 SECOND STREET | CAMBRIDGE | MA | 02142 | MIDDLESEX | USA | R43HD046194 | NOREPINEPHRINE TRANSPORTERS: TARGETS FOR ADHD | 000 | 1 | NIH | 6/28/2004 | $301,412 |
|
|
